Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: SyB L-0501
Drug: prednisolone

Registration Number: NCT01179490

Lead Sponsor: SymBio Pharmaceuticals

Brief Summary: The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.

Detailed Description: The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for untreated and maladjustment to hematopoietic stem cell transplantation (HSCT) multiple myeloma to a regimen of bendamustine and prednisolone.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 5

Inclusion Criteria

Patients are included in the study if all of the following criteria are met: Patients confirmed to have multiple myeloma (symptomatic myeloma) defined in the diagnostic criteria of the International Myeloma Working Group (IMWG).

Patients with measurable lesions
Patients with no history of treatment (no history of chemotherapy or radiotherapy)
Patients should not be considered candidates for high dose therapy/autologous stem cell transplantation due to coexistent medical conditions, advanced age, poor performance status, refusal of high dose chemotherapy, or other reasons as judged by the patient and/or physician.
Expected survival of at least 3 months
Patients aged between 20 and 79 years (at the time of provisional registration)
Performance status (P.S.) grade 0-2. P.S. 3 possible only for osteolytic lesions
Patients with adequately maintained organ function (e.g., bone marrow, heart, lungs, liver, kidneys,)
Patients from whom written consent to participate in this study has been obtained.

Exclusion Criteria

Patients are excluded from participating in the study if 1 or more of the following criteria are met:

Patients with apparent infections (including viral infections)
Patients with serious complications (hepatic failure, renal failure, or diabetes with insulin administration)
Patients with complications or a medical history of serious cardiac disease (e.g., myocardial infarction, ischemic heart disease) within 2 years before preliminary registration. Patients with arrhythmia requiring treatment.
Patients with serious gastrointestinal symptoms (profound or serious nausea / vomiting or diarrhea, etc.)
Patients who were hepatitis B virus antigen (HBsAG)-positive, hepatitis C virus (HCV) antibody-positive or human immunodeficiency virus (HIV) antibody-positive
Patients with a serious bleeding tendency [e.g., Disseminated intravascular coagulation (DIC)]
Patients with interstitial pneumonia, pulmonary fibrosis or pulmonary emphysema requiring treatment, or such diseases in the past
Patients with apparent amyloidosis as a complication
Patients with clinical symptoms of invasion or suspected invasion of the central nervous system.
Patients with active multiple cancers
Patients who have or previously had autoimmune hemolytic anemia.
Patients administered this investigational drug in the past
Patients who received hematopoietic stem cell transplantation in the past.
Patients who received cytokines such as granulocyte colony stimulating factor (G-CSF) or erythropoietin or a blood transfusion within 1 week before the screening examination prior to preliminary registration for this study
Patients who were administered an investigational drug during a clinical study or an unapproved drug within 3 months prior to preliminary registration in this study
Patients with prior allergies to medications similar to the investigational drug (e.g., alkylating agents, or purine nucleotide analogs), mannitol or prednisolone
Patients with drug addiction, narcotic addiction or alcoholism.
Patients who were pregnant, breastfeeding women or who had a possibility to be pregnant
Patients who do not agree to contraception during the following periods. For males, during or for 6 months after completion of administration of the investigational drug. For females, during or for 3 months after completion of administration of the investigational drug
Patients whom the investigator or the sub-investigators considered to be inappropriate for the study

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SyB L-0501 + prednisolone	SyB L-0501	SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
SyB L-0501 + prednisolone	prednisolone	SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.

Primary Outcome Measures

Name	Time	Method
Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria]	Up to 36 weeks	The proportion of subjects evaluated as CR was calculated. CR (modified SWOG) requires all of the followings: 1. Decline in serum myeloma protein by ≥75% to ≤25 g/L 2. Reduction in 24 h urinary protein by ≥90% to ≤200 mg/24 h 3. No increase in skeletal destruction 4. Serum calcium within normal range 5. No blood transfusion required in the previous 3 months

Secondary Outcome Measures

Name	Time	Method
CR Rate [Based on the International Myeloma Working Group (IMWG) Criteria]	Up to 36 weeks	The proportion of subjects evaluated as CR \[strict CR (sCR) + CR\] was calculated. sCR (IMWG): CR as defined below plus Normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence CR (IMWG): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow
Response Rate (Based on the IMWG Criteria)	Up to 36 weeks	The proportion of subjects evaluated as response \[sCR + CR + very good partial response (VGPR) + Partial Response (PR)\] was calculated. VGPR (IMWG): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100mg per 24 h PR (IMWG): ≥50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥90% or to \<200mg per 24 h
CR Rate Based on the (Bladé) Criteria	Up to 36 weeks	The proportion of subjects evaluated as CR was calculated. CR (Bladé) requires all of the followings: 1. Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks. The presence of oligoclonal bands consistent with oligoclonal immune reconstitution does not exclude CR. 2. \<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy is performed. If absence of monoclonal protein is sustained for 6 weeks it is not necessary to repeat the bone marrow, except in patients with non-secretory myeloma where the marrow examination must be repeated after an interval of at least 6 weeks to confirm CR. 3. No increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response) 4. Disappearance of soft tissue plasmacytomas
Response Rate (Based on the Bladé Criteria)	Up to 36 weeks	The proportion of subjects evaluated as response (CR + PR) was calculated. PR (Bladé) requires 1. or all of the others: 1. Some, but not all, of the criteria for CR are fulfilled 2. ≥50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks. 3. Reduction in 24 h urinary light chain excretion either by ≥90% or to \<200 mg, maintained for a minimum of 6 weeks. 4. For patients with non-secretory myeloma only, ≥50% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 weeks. 5. ≥50% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination). 6. No increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response).
Response Rate (Based on the Modified SWOG Criteria)	Up to 36 weeks	The proportion of subjects evaluated as response (CR + PR) was calculated. PR (SWOG) requires the followings: 1. Decline in myeloma protein of ≥25%-\<74% in serum myeloma protein 2. Reduction in 24h urinary myeloma protein of ≥25%-\<89% 3. No increase in skeletal destruction 4. Serum calcium within normal range
Progression-Free Survival (PFS)	Up to 2 years	PFS is the period from patient registration to either the date of recurrence, exacerbation, progression or death. Recurrence, exacerbation, progression were assessed from serum M-protein, urine M-protein, serum free light chain (FLC), the percentage of marrow plasma cells, disappearance of clonal plasma cells, plasma cell tumor in soft tissue, and bone lesion.
Time to Treatment Failure (TTF)	Up to 2 years	TTF is the period from patient registration to either the date of recurrence, exacerbation, progression, death or discontinuation of treatment.
Duration of Response (DOR)	Up to 2 years	DOR is the period from the date of achieving CR or PR to either the date of recurrence, exacerbation, progression or death.
Overall Survival (OS)	Up to 2 years	OS is the period from the date of patient registration to the date of death.
Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event	Up to 2 years	Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.02, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA).
Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events	Up to 2 years	Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.02, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA).
Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values	Up to 2 years	Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. grade 1 : mild grade 2 : moderate grade 3 : severe or medically significant but not immediately life-threatening grade 4 : life threatening or disabling grade 5 : death related to AE
Number of Abnormalities (Grade ≥3) in Laboratory Test Values	Up to 2 years	Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE.
Pharmacokinetic Parameters (Cmax)	On Day 1 only	Plasma pharmacokinetics (Cmax) of unchanged bendamustine
Pharmacokinetic Parameters (Tmax)	On Day 1 only	Plasma pharmacokinetics (tmax) of unchanged bendamustine
Pharmacokinetic Parameters (AUC)	On Day 1 only	Plasma pharmacokinetics (AUC) of unchanged bendamustine
Pharmacokinetic Parameters (t1/2)	On Day 1 only	Plasma pharmacokinetics (t1/2) of unchanged bendamustine